Licochalcone a prevents adipocyte differentiation and lipogenesis via suppression of peroxisome proliferator-activated receptor γ and sterol regulatory element-binding protein pathways

Journal of Agricultural and Food Chemistry

Volumn 60, Issue 20, 2012, Pages 5112-5120

  Quan, Hai Yan ^a   Baek, Nam In ^a   Chung, Sung Hyun ^a  

^a Kyung Hee University   (South Korea)

Author keywords

3T3 L1 preadipocytes; adipocyte differentiation; CCAAT enhancer binding protein ; licochalcone A; peroxisome proliferator activated receptor

Indexed keywords

ALCOHOLS; COMPUTERIZED TOMOGRAPHY; CYTOLOGY; GENE EXPRESSION; MAMMALS; MEDICAL APPLICATIONS; MOLECULAR WEIGHT; PLANTS (BOTANY); PROTEINS;

3T3-L1 PREADIPOCYTES; ADIPOCYTE DIFFERENTIATION; CCAAT/ENHANCER-BINDING PROTEINS; LICOCHALCONE A; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR;

FATTY ACIDS;

ANIMALIA; MUS;

EID: 84861418466     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf2050763     Document Type: Article

References (33)

1. James, P. T.; Rigby, N.; Leach, R. for the International Obesity Task Force. The obesity epidemic metabolic syndrome and future prevention strategies Eur. J. Cardiovasc. Prev. Rehabil. 2004, 11, 3-8
2. World Health Organization factsheet 311 - obesity and overweight; available from www.who.int/mediacentre/factsheets/fs311/en/index.html.
3. Medina-Gomez, G.; Vidal-Puig, A. Gateway to the metabolic syndrome Nat. Med. 2005, 11, 602-603
4. Hsu, Y. W.; Chu, D. C.; Ku, P. W.; Liou, T. H.; Chou, P. Pharmacotherapy for obesity: past, present and future J. Exp. Clin. Med. 2010, 2, 118-123
5. Shibata, S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice Yakugaku Zasshi 2000, 120, 849-862
6. Kim, S. N.; Bae, S. J.; Kwak, H. B.; Min, Y. K.; Jung, S. H.; Kim, C. H.; Kim, S. H. In vitro and in vivo osteogenic activity of licochalcone A Amino Acids 2012, 42, 1455-1465
7. Kolbe, L.; Immeyer, J.; Batzer, J.; Wensorra, U.; tom Dieck, K.; Mundt, C.; Wolber, R.; Stäb, F.; Schönrock, U.; Ceilley, R. I.; Wenck, H. Anti-inflammatory efficacy of licochalcone A: correlation of clinical potency and in vitro effects Arch. Dermatol. Res. 2006, 298, 23-30
8. Funakoshi-Tago, M.; Nakamura, K.; Tsuruya, R.; Hatanaka, M.; Mashino, T.; Sonoda, Y.; Kasahara, T. The fixed structure of licochalcone A by α,Î-unsaturated ketone is necessary for anti-inflammatory activity through the inhibition of NF-ΰB activation Int. Immunopharmacol. 2010, 10, 562-571
9. Mi-Ichi, F.; Miyadera, H.; Kobayashi, T.; Takamiya, S.; Waki, S.; Iwata, S.; Shibata, S.; Kita, K. Parasite mitochondria as a target of chemotherapy: inhibitory effect of licochalcone A on the Plasmodium falciparum respiratory chain Ann. N.Y. Acad. Sci. 2005, 1056, 46-54
10. Messier, C.; Grenier, D. Effect of licorice compounds licochalcone A, glabridin and glycyrrhizic acid on growth and virulence properties of Candida albicans Mycoses 2011, 54, e801-e806
11. Kim, Y. H.; Shin, E. K.; Kim, D. H.; Lee, H. H.; Park, J. H.; Kim, J. K. Antiangiogenic effect of licochalcone A Biochem. Pharmacol. 2010, 80, 1152-1159
12. Yoon, G.; Kang, B. Y.; Cheon, S. H. Topoisomerase I inhibition and cytotoxicity of licochalcones A and E from Glycyrrhiza inflata Arch. Pharm. Res. 2007, 30, 313-316
13. Lee, Y. S.; Kim, S. H.; Jung, S. H.; Kim, J. K.; Pan, C. H.; Lim, S. S. Aldose reductase inhibitory compounds from Glycyrrhiza uralensis Biol. Pharm. Bull. 2010, 33, 917-921
14. Judex, S.; Luu, Y. K.; Ozcivici, E.; Adler, B.; Lublinsky, S.; Rubin, C. T. Quantification of adiposity in small rodents using micro-CT Methods 2010, 50, 14-19
15. Luu, Y. K.; Lublinsky, S.; Ozcivici, E.; Capilla, E.; Pessin, J. E.; Rubin, C. T.; Judex, S. In vivo quantification of subcutaneous and visceral adiposity by micro-computed tomography in a small animal model Med. Eng. Phys. 2009, 31, 34-41
16. Timar, R. Obezitatea adultului. In Clinica Medicala. Teorie si Practica; Serban, V.; Babes, P. A., Eds.; Editura de Vest: Timisoara, Romania, 1999; pp 83-198.
17. World Health Organization. Global Strategy on Diet, Physical Activity and Health; WHO: Geneva, Switzerland, 2007.
18. Park, T.; Kim, Y. Phytochemicals as potential agents for prevention and treatment of obesity and metabolic diseases. Anti-Obesity Drug Discovery and Development; Bentham Science: Oak Park, IL, 2011; p 1.
19. Santos, A. S.; Rogero, M. M.; Bastos, D. H. Edible plants, their secondary metabolites and anti-obesogenic potential Recent Pat. Food Nutr. Agric. 2010, 23, 195-212
20. Rayalam, S.; Della-Fera, M. A.; Baile, C. A. Phytochemicals and regulation of the adipocyte life cycle J. Nutr. Biochem. 2008, 19, 717-726
21. Nowakowska, Z. A review of anti-infective and anti-inflammatory chalcones Eur. J. Med. Chem. 2007, 42, 125-137
22. Ehrenkranz, J. R.; Lewis, N. G.; Kahn, C. R.; Roth, J. Phlorizin: a review Diabetes Metab. Res. Rev. 2005, 21, 31-38
23. Vaidya, H. B.; Goyal, R. K. Exploring newer target sodium glucose transporter 2 for the treatment of diabetes mellitus Mini Rev. Med. Chem. 2010, 10, 905-913
24. Waters, E.; de Silva-Sanigorski, A.; Hall, B. J.; Brown, T.; Campbell, K. J.; Gao, Y.; Armstrong, R.; Prosser, L.; Summerbell, C. D. Interventions for preventing obesity in children Cochrane Database Syst. Rev. 2011, 12, CD001871
25. Lazarou, C.; Panagiotakos, D.; Matalas, A. L. The role of diet in prevention and management of type 2 diabetes: implications for public health Crit. Rev. Food Sci. Nutr. 2012, 52, 382-389
26. Weisberg, S. P.; McCann, D.; Desai, M.; Rosenbaum, M.; Leibel, R. L.; Ferrante, A. W., Jr. Obesity is associated with macrophage accumulation in adipose tissue J. Clin. Invest. 2003, 112, 1796-1808
27. Fox, C. S.; Massaro, J. M.; Hoffmann, U.; Pou, K. M.; Maurovich-Horvat, P.; Liu, C. Y.; Vasan, R. S.; Murabito, J. M.; Meiqs, J. B.; Cupples, L. A.; D'Aqostino, R. B., Sr.; O'Donnell, C. J. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study Circulation 2007, 116, 39-48
28. Mohammed, B. S.; Cohen, S.; Reeds, D.; Young, V. L.; Klein, S. Long-term effects of large-volume liposuction on metabolic risk factors for coronary heart disease Obesity 2008, 16, 2648-2651
29. Despres, J. P. Cardiovascular disease under the influence of excess visceral fat Crit. Pathways Cardiol. 2007, 6, 51-59
30. Demerath, E. W.; Reed, D.; Rogers, N.; Sun, S. S.; Lee, M.; Choh, A. C.; Couch, W.; Czerwinski, S. A.; Chumlea, W. C.; Siervoqel, R. M.; Towne, B. Visceral adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels Am. J. Clin. Nutr. 2008, 88, 1263-1271
31. Jo, J.; Gavrilova, O.; Pack, S.; Jou, W.; Mullen, S.; Sumner, A. E.; Cushman, S. W.; Periwal, V. Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth PLoS Comput. Biol. 2009, 5, e1000324
32. Gesta, S.; Tseng, Y. H.; Kahn, C. R. Developmental origin of fat: tracking obesity to its source Cell 2007, 131, 242-256
33. McGarry, J. D.; Brown, N. F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis Eur. J. Biochem. 1997, 244, 1-14